MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-11-2026
Organovo Holdings Cost of Revenue 2011-2026 | ONVO
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Organovo Holdings
| 2025 | 2024 | 2023 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5 K | - | - | - | 300 K | 500 K | 1.03 M | 956 K | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.03 M | 5 K | 558 K |
Quarterly Cost of Revenue Organovo Holdings
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 2 K | 1 K | 2 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 13 K | 300 K | 300 K | 100 K | 100 K | 100 K | 100 K | - | 200 K | 300 K | 300 K | - | 212 K | 773 K | 561 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 773 K | 1 K | 210 K |
Cost of Revenue of other stocks in the Diagnostics research industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
162 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Accelerate Diagnostics
AXDX
|
9.45 M | - | -61.36 % | $ 2.46 M |  USA |
 |
Agilent Technologies
A
|
2.91 B | $ 117.74 | -1.68 % | $ 35.8 B | USA |
 |
Burning Rock Biotech Limited
BNR
|
144 M | $ 19.95 | -2.97 % | $ 211 M |  China |
 |
Aspira Women's Health
AWH
|
3.3 M | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
28.4 M | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
38.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
DermTech
DMTK
|
15 M | - | -11.32 % | $ 2.94 M | USA |
 |
CareDx, Inc
CDNA
|
45.5 M | $ 22.11 | 25.81 % | $ 1.18 B | USA |
|
Akumin
AKU
|
608 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Exact Sciences Corporation
EXAS
|
984 M | - | - | $ 19.8 B | USA |
 |
Enzo Biochem
ENZ
|
17.3 M | - | -8.98 % | $ 14.8 K | USA |
 |
Co-Diagnostics
CODX
|
222 K | $ 1.42 | - | $ 1.89 M | USA |
 |
Castle Biosciences
CSTL
|
60.2 M | $ 24.49 | -0.53 % | $ 680 M | USA |
 |
Global Cord Blood Corporation
CO
|
183 M | - | - | $ 399 M | China |
 |
Genetic Technologies Limited
GENE
|
276 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
194 M | - | 0.12 % | $ 80.1 M | China |
 |
Danaher Corporation
DHR
|
10 B | $ 194.65 | -1.74 % | $ 139 B | USA |
 |
Interpace Biosciences
IDXG
|
14.6 M | $ 1.93 | -12.09 % | $ 8.54 M | USA |
 |
Heska Corporation
HSKA
|
146 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
4.57 M | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
1.51 B | $ 130.0 | -1.71 % | $ 20.7 B | USA |
 |
Fulgent Genetics
FLGT
|
176 M | $ 16.04 | -0.8 % | $ 485 M | USA |
 |
NeoGenomics
NEO
|
413 M | $ 8.39 | -3.34 % | $ 1.07 B | USA |
 |
Neogen Corporation
NEOG
|
473 M | $ 9.18 | -2.55 % | $ 1.99 B | USA |
 |
Guardant Health
GH
|
349 M | $ 85.27 | 0.48 % | $ 10.7 B | USA |
 |
QIAGEN N.V.
QGEN
|
801 M | - | - | $ 10.6 B |  Niderland |
 |
Biomerica
BMRA
|
4.81 M | $ 2.19 | 4.03 % | $ 5.03 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
9.99 B | $ 29.07 | - | $ 20 B | Niderland |
 |
ICON Public Limited Company
ICLR
|
3.97 B | $ 115.89 | -0.52 % | $ 9.56 B |  Irlanda |
 |
Laboratory Corporation of America Holdings
LH
|
9.94 B | $ 267.91 | 0.38 % | $ 22.3 B | USA |
 |
Motus GI Holdings
MOTS
|
81 K | - | -34.28 % | $ 263 K |  Israel |
 |
Senseonics Holdings
SENS
|
19.5 M | $ 6.78 | -1.74 % | $ 283 M | USA |
 |
Myriad Genetics
MYGN
|
248 M | $ 5.16 | -0.67 % | $ 478 M | USA |
 |
Lantheus Holdings
LNTH
|
600 M | $ 83.51 | -0.51 % | $ 5.64 B | USA |
 |
Soleno Therapeutics
SLNO
|
2.7 M | $ 52.62 | 0.1 % | $ 2.67 B | USA |
 |
Neuronetics
STIM
|
76.8 M | $ 1.36 | -2.52 % | $ 89.7 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
7.37 B | $ 193.55 | 1.16 % | $ 21.5 B | USA |
 |
ENDRA Life Sciences
NDRA
|
173 K | $ 5.2 | 1.17 % | $ 4.09 M | USA |
 |
Invitae Corporation
NVTA
|
92.8 M | - | - | $ 21.2 M | USA |